Table 1 Baseline characteristics of patients with PCOS based on the treatment groups
| Baseline characteristics |
EE 30 μg + LNG 0.15 mg (n = 26) |
EE 30 μg + DSG 150 μg (n = 26) |
EE 35 μg + CPA 2 mg (n = 20) |
EE 30 μg + DRSP 3 mg (n = 16) | Total | €P-value |
|---|---|---|---|---|---|---|
| Age, years | 28 (24–33) | 28 (23–34) | 30 (27–36) | 32 (24–37) | 29 (25–34) | 0.125 |
| BMI, kg/m2 | 25 (23–27) | 24 (21–29) | 25 (23–28) | 26 (22–30) | 25 (22–28) | 0.251 |
| Education | ||||||
| Diploma and less | 0 (0) | 2 (7.7) | 1 (5.0) | 2 (12.5) | 5 (5.7) | 0.085 |
| Upper diploma | 26 (100) | 24 (92.3) | 19 (95.0) | 14 (87.5) | 83 (94.3) | |
| Marital status | ||||||
| Never married | 14 (53.8) | 14 (53.8) | 8 (40.0) | 10 (62.5) | 46 (52.3) | 0.471 |
| Ever married | 12 (46.2) | 12 (46.2) | 12 (60.0) | 6 (37.5) | 42 (47.7) | |
| Parity | ||||||
| Nulliparous | 3 (25.0) | 4 (33.3) | 0 (0) | 4 (57.1) | 11 (26.2) | 0.854 |
| Primiparous | 6 (50.0) | 4 (33.3) | 7 (63.6) | 2 (28.6) | 19 (45.2) | |
| Multiparous | 3 (25.0) | 4 (33.3) | 4 (36.4) | 1 (14.3) | 12 (28.6) | |
| Job | ||||||
| Student | 6 (23.1) | 5 (19.2) | 3 (15.0) | 2 (12.5) | 16 (18.2) | 0.521 |
| Employed | 11 (42.3) | 10 (38.5) | 8 (40.0) | 3 (18.8) | 32 (36.4) | |
| Housewife | 9 (34.6) | 11 (42.3) | 9 (45.0) | 11 (68.8) | 40 (45.5) | |
| Infertility status | ||||||
| yes | 3 (11.5) | 3 (11.5) | 2 (10.0) | 1 (6.3) | 9 (10.2) | 0.147 |
| no | 23 (88.5) | 23 (88.5) | 18 (90.0) | 15 (93.8) | 79 (89.8) | |
| Duration of infertility, years | 8 (4–36) | 5 (4–18) | 24 (24–24) | 36 (36–36) | 18 (5–24) | |
| Menstrual disorder | ||||||
| yes | 24 (92.3) | 26 (100) | 20 (100) | 16 (100) | 86 (97.7) | 0.652 |
| no | 2 (7.7) | 0 (0) | 0 (0) | 0 (0) | 2 (2.3) | |
| Duration of Menstrual disorder, months | 120 (60–162) | 102 (36–156) | 147 (72–204) | 157 (42–180) | 120 (48–180) | 0.124 |
| Duration of PCOS diagnosis, months | 36 (22–96) | 36 (1–54) | 30 (12–60) | 60 (24–108) | 36 (12–87) | 0.321 |
| FSH | 4 (4–5) | 5 (4–6) | 5 (4–6) | 4 (4–5) | 5 (4–6) | 0.146 |
| LH | 4 (2–8) | 4 (3–6) | 4 (3–6) | 3 (2–4) | 4 (3–6) | 0.858 |
| Total testosterone, ng/ml | 1 (0–1) | 1 (1–1) | 1 (1–1) | 0 (0–1) | 1 (0–1) | |
| SHBG (nmo/l) | 32 (16–48) | 53 (34–95) | 53 (34–95) | 50 (26–68) | 44 (27–67) | 0.069 |
| FAI | 6 (3–10) | 4 (2–8) | 4 (2–8) | 4 (1–6) | 4 (2–8) | 0.598 |
| DHEAS | 183 (111–229) | 138 (94–216) | 138 (94–216) | 138 (73–178) | 153 (94–206) | 0.075 |
| FBS, mg/dL | 86 (76–91) | 86 (78–92) | 86 (78–92) | 89 (80–98) | 86 (78–93) | 0.152 |
| Fasting Insulin | 8 (6–14) | 7 (6–13) | 7 (6–13) | 9 (6–15) | 9 (6–13) | 0.085 |
| HOMA-IR | 2 (1–3) | 1 (1–3) | 1 (1–3) | 2 (1–3) | 2 (1–3) | 0.895 |
| TG, mg/dL | 76 (60–104) | 95 (60–142) | 95 (60–142) | 89 (80–120) | 82 (69–122) | 0.064 |
| TC, mg/dL | 176 (141–199) | 170 (147–202) | 170 (147–202) | 162 (147–174) | 169 (146–196) | 0.098 |
| LDL, mg/dL | 99 (77–114) | 93 (83–115) | 93 (83–115) | 91 (80–100) | 92 (78–112) | 0.581 |
| HDL, mg/dL | 48 (41–52) | 47 (39–56) | 47 (39–56) | 43 (38–50) | 46 (39–52) | 0.236 |